A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet